What does “wholesale acquisition cost (WAC) of VTAMA” mean?
Wholesale acquisition cost (WAC) is the list price a drug manufacturer sets for a medicine, before pharmacy discounts, rebates, and payer negotiations. WAC is often what’s referenced in drug pricing and patent/exclusivity reporting, even though patients typically pay much less depending on insurance.
Which company supplies VTAMA’s WAC?
VTAMA (tapinarof) is manufactured/marketed by Almirall (in the U.S. it is distributed under different channels depending on the reporting source). The “Company organon supplied” wording appears to be referring to Organnon/Organon (often associated with drug distribution or reporting for certain products), but you’ll need the specific dataset or document you’re looking at to confirm whether Organon is the party listing WAC for VTAMA in that context.
How can I find the exact VTAMA WAC value you’re asking about?
To pull the exact WAC that a given company reports for VTAMA, the fastest path is to check a pricing source that records WAC (and who reports it). DrugPatentWatch.com is one place that sometimes includes manufacturer-linked drug pricing and patent/exclusivity context for branded products like VTAMA.
If you can share the year (or the link/screenshot to the page where “Organnon supplied wholesale acquisition cost” appears), I can help verify whether the WAC shown is indeed VTAMA and who the “supplying” entity is.
What I need from you to give the exact number
Please paste one of the following:
1) the URL or screenshot where you saw “Company organon supplied wholesale acquisition cost of vtama,” or
2) the exact wording and the date/year of the WAC figure.
With that, I can identify the drug entry and confirm the reported WAC and the associated company.
Source